ObjectiveTo systematically compare the incidence, microbiological profile, and outcomes of infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR). MethodsA systematic literature search was conducted in the CNKI, Wanfang, VIP, SinoMed, PubMed, the Cochrane Library, Embase, and Web of Science databases for relevant studies published from their inception to August 2025. Two reviewers independently screened the literature, extracted data, and assessed the quality of the included studies. The quality of cohort studies was evaluated using the modified Newcastle-Ottawa Scale (NOS), and randomized controlled trials (RCTs) were assessed using the Cochrane Risk of Bias tool 2 (RoB 2). A meta-analysis was performed using Stata 19.0. ResultsA total of 12 cohort studies and 1 RCT, encompassing over 200 000 patients, were included. The modified NOS scores for all cohort studies were ≥7 points, and the RCT was rated as having a low overall risk of bias. The overall incidence of IE was significantly lower after TAVR than that after SAVR [RR=0.73, 95%CI (0.59, 0.90), P<0.01]. However, early IE (within 12 months) occurred more frequently following TAVR, though the difference was not statistically significant [RR=1.23, 95%CI (0.87, 1.75), P=0.24]. Reoperation for IE was markedly less common in the TAVR group [RR=0.31, 95%CI (0.20, 0.47), P<0.01]. There were no significant differences in in-hospital mortality or 1-year mortality between the two groups. Regarding the microbiological profile, no significant differences were observed in the distribution of Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus spp., and Enterococcus spp. (P>0.01). ConclusionTAVR is associated with a lower overall risk of IE but a higher risk of early IE compared to SAVR. Although reoperation is less common in TAVR patients, mortality rates are comparable. The microbiological etiology is consistent between procedures.
ObjectiveTo construct a preoperative objective index-based model for predicting the mortality risk of aortic dissection, aiming to provide a quick risk assessment tool for primary healthcare. MethodsA total of 271 patients with thoracic aortic dissection from the Medical Information Mart for Intensive Care (MIMIC-Ⅳ) database between 2008 and 2019 were included. These patients were randomly divided into a training set, a validation set, and a test set at a ratio of 7:2:1. Based on the Akaike information criterion (AIC), forward regression was used to select the risk factors for patients with post-dissection mortality, and the XGBoost algorithm was employed to establish the prediction model. The SHAP (SHapley Additive exPlanation) theory was used for interpretive analysis. ResultsOut of the 271 patients of aortic dissection, 158 were males and 113 were females, with a median age of 70.3 (58.8, 79.5) years. The training set, validation set, and test set consisted of 189, 54, and 28 patients respectively. During the follow-up period, 99 deaths (36.5%) occurred. Using the forward stepwise regression based on the AIC criterion, 18 preoperative independent predictors were identified. An XGBoost prediction model was constructed accordingly. After grid search optimization, the model demonstrated good discrimination and calibration in both the validation set [area under the curve (AUC)=0.681] and the test set (AUC=0.735). The SHAP analysis indicated that age (SHAP=0.081), activated partial thromboplastin time (SHAP=0.065), and red cell distribution width (SHAP=0.038) were the top three predictive contributors. ConclusionThe aortic dissection mortality risk prediction model constructed based on the XGBoost algorithm can effectively predict the incidence of mortality outcomes. Characteristic indicators such as age, activated partial thromboplastin time, and red cell distribution width can assist clinicians in identifying high-risk patients, making triage referral decisions, and optimizing preoperative interventions within the golden time window, ultimately aiming to reduce the mortality rate of patients with aortic dissection.
Objective To systematically evaluate the clinical effects of remote ischaemic preconditioning (RIPC) in elective vascular surgery. Methods Electronic searches were conducted in The Cochrane Library, PubMed, EMbase, Web of Science, CNKI, Wanfang Data, VIP Database, and CBM. Relevant randomized controlled trials (RCTs) were screened according to inclusion and exclusion criteria. Meta-analysis was performed using RevMan 5.3 software, and the risk of bias was assessed using the Cochrane risk of bias tool. Results A total of 15 studies involving 1 382 patients were included. The meta-analysis results showed no statistically significant difference between RIPC and non-RIPC groups in reducing perioperative mortality in elective vascular surgery (P>0.05). There were also no statistically significant differences between the two groups of vascular surgery patients regarding the incidence of myocardial infarction, renal injury, postoperative stroke, postoperative length of hospital stay, duration of surgery or total anesthesia time, or the incidence of limb injury, arrhythmia, heart failure, and pneumonia (P>0.05). Conclusion For patients undergoing elective vascular surgery, there are no significant differences between RIPC and non-RIPC in terms of perioperative mortality and other clinical endpoint outcomes.
ObjectiveTo systematically evaluate the therapeutic effects of different surgical procedures for ischemic mitral regurgitation (IMR). MethodsComputer searches were conducted in CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, Embase, and Web of Science, with the search time limit from the inception of the databases to February 2024. Two researchers independently screened the literature, extracted data, used the Cochrane bias risk assessment tool to evaluate the quality of the included studies, and used Stata 17.0 software to analyze the data. ResultsA total of 19 randomized controlled trials involving 6139 patients were finally included, involving six surgical procedures, and the overall quality of the included studies was relatively high. The results of the network meta-analysis showed that the 30-day all-cause mortality rate of mitral valve repair (MVr) was significantly lower than that of coronary artery bypass grafting (CABG) [OR=0.24, 95%CI (0.07, 0.87), P<0.01], mitral valve replacement (MVR) [OR=0.43, 95%CI (0.23, 0.79), P=0.02], CABG+MVR [OR=0.21, 95%CI (0.04, 0.95), P=0.03] and transcatheter mitral valve edge-to-edge repair (TEER) using MitraClip [OR=0.13, 95%CI (0.02, 0.87), P<0.01]. The 30-day all-cause mortality rate of CABG+MVr was significantly lower than that of CABG [OR=0.56, 95%CI (0.33, 0.93), P=0.02] and CABG+MVR [OR=0.48, 95%CI (0.24, 0.94), P=0.04], and the best probability ranking results showed that MVR might be the most effective in reducing the 30-day all-cause mortality rate. The incidence of renal complications in CABG+MVr was significantly lower than that in CABG+MVR [OR=0.42, 95%CI (0.21, 0.83), P=0.01]; the best probability ranking results showed that CABG+MVr might be the most effective in reducing renal complications. ConclusionThe current limited evidence suggests that CABG+MVr and MVr may be the best surgical intervention methods for IMR patients at present. Due to the limitations of the number and quality of included studies, the above conclusions still need to be verified by more high-quality studies.
ObjectiveTo systematically evaluate the differences in outcomes between functional mitral regurgitation (FMR) and degenerative mitral regurgitation (DMR) in patients treated with transcatheter edge-to-edge repair (TEER) using the MitraClip device. MethodsA systematic literature search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, the CNKI, Wanfang Database, VIP Database, and the CBM from their inception to January 2024. Two researchers independently performed study selection, data extraction, and risk of bias assessment. The quality of cohort studies was evaluated using the Newcastle-Ottawa Scale (NOS). A meta-analysis was performed using Stata 18.0 software. ResultsA total of 13 cohort studies involving 6 402 patients were included, comprising 4 161 patients in the FMR group and 2 241 in the DMR group. All included studies had NOS scores of ≥6 points. The meta-analysis revealed that compared to the DMR group, the FMR group had a higher 1-year all-cause mortality rate [OR=1.53, 95%CI (1.30, 1.81), P＜0.01] and a higher 1-year rehospitalization rate for heart failure [OR=1.90, 95%CI (1.60, 2.26), P＜0.01]. Conversely, the FMR group had a lower post-procedural mean transmitral gradient [SMD=–0.47, 95%CI (–0.65, –0.30), P＜0.01] and a lower rate of subsequent mitral valve surgery [OR=0.41, 95%CI (0.20, 0.83), P=0.01]. ConclusionFollowing MitraClip therapy, patients with FMR exhibit favorable short-term outcomes, but their mid- to long-term outcomes are inferior to those of patients with DMR. When determining the treatment strategy with MitraClip, the specific etiology of mitral regurgitation should be considered for a more accurate prediction of therapeutic efficacy and prognosis.
Objective To systematically evaluate the impact of pulmonary hypertension (PH) on the prognosis of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Methods A computerized search was conducted in CNKI, Wanfang Data, VIP, CBM, PubMed, The Cochrane Library, EMbase, and Web of Science databases from inception to June 2023 for cohort studies on the prognostic impact of PH in severe AS patients undergoing TAVR. Two researchers independently screened the literature, extracted data, and assessed the quality of included studies. Stata 17.0 software was used for meta-analysis. Results A total of 16 cohort studies were included, all with Newcastle-Ottawa Scale scores≥7. Meta-analysis results showed that, compared with AS patients without PH, those with PH had significantly higher 1-year all-cause mortality after TAVR [OR=2.10, 95%CI (1.60, 2.75), P<0.01], 30-day all-cause mortality [OR=2.09, 95%CI (1.54, 2.83), P<0.01], and cardiovascular mortality [OR=1.49, 95%CI (1.18, 1.90), P<0.01]. The differences between the two groups in major bleeding events, stroke, myocardial infarction, pacemaker implantation, and postoperative renal failure were not statistically significant. For outcome indicators with significant heterogeneity, subgroup analyses were performed based on PH measurement methods, diagnostic criteria, and different types of PH. The results showed that most subgroup combined results were consistent with the overall findings and that heterogeneity was significantly reduced. Conclusion PH significantly increases the 30-day all-cause mortality, 1-year all-cause mortality, and cardiovascular mortality in patients with severe AS undergoing TAVR.
ObjectiveTo evaluate the clinical outcomes of sutureless aortic valve replacement (SU-AVR) and transcatheter aortic valve implantation (TAVI) for aortic valve disease. MethodsWe conducted a computer-based search of databases including CNKI, WanFang Data, VIP, CBM, PubMed, The Cochrane Library, EMbase and Web of Science from the inception of the databases to March 2024. Two reviewers independently screened articles, extracted data and used the Cochrane bias risk assessment tool to evaluate the quality of the included studies. Meta-analysis was performed using Stata 18 software. ResultsThe included 17 studies using propensity-matched analysis consisted of 6 630 patients, including 3 319 patients in the SU-AVR group and 3 311 patients in the TAVI group. The SU-AVR group had lower mortality than the TAVI group at 1-year ［RR=0.58, 95%CI(0.38, 0.87), P=0.009］, 2-year ［RR=0.61, 95%CI(0.43,0.85), P=0.004］ and 5-year ［RR=0.63, 95%CI(0.50,0.79), P=0.000］. The SU-AVR group had a significantly lower rate of new permanent pacemaker implantation (PPI) ［RR=0.75, 95%CI(0.58, 0.98), P=0.037］, moderate-to-severe paravalvular leak (PVL) ［RR=0.20, 95%CI（0.12, 0.32）, P=0.000］, myocardial infarction(MI)［RR=0.30, 95%CI (0.11,0.80), P=0.017］, more-than-mild residual aortic regurgitation (AR)［RR=0.29, 95%CI（0.17, 0.48）, P=0.000］. In addition, the SU-AVR group had a higher postoperative mean aortic gradient [SMD=0.39, 95%CI (0.17, 0.62), P=0.000］than the TAVI group. Conclusion The early and mid-term clinical outcomes of SU-AVR were superior compared to TAVI.